Healthequity Inc (HQY) valuation
Healthequity P/E ratio history
Healthequity trades at 37.0 times its earnings over the last twelve months and 20.0 times the earnings analysts expect over the next twelve. At its last 7 fiscal year ends its P/E ranged from 34.8 (year to Jan 2026) to 118.1 (year to Jan 2024), with a median of 101.3.
| Fiscal year ended | Price | EPS | P/E | Forward P/E |
|---|---|---|---|---|
| Jan 31, 2026 | $85.67 | $2.46 | 34.8 | 19.5 |
| Jan 31, 2025 | $110.42 | $1.09 | 101.3 | 31.1 |
| Jan 31, 2024 | $75.58 | $0.64 | 118.1 | 29.1 |
| Jan 31, 2023 | $60.85 | -$0.31 | n/m | 36.3 |
| Jan 31, 2022 | $53.44 | -$0.53 | n/m | 36.9 |
| Jan 31, 2021 | $83.55 | $0.12 | n/m | — |
| Jan 31, 2020 | $66.06 | $0.65 | 101.6 | — |
| Jan 31, 2019 | $62.34 | $1.18 | 52.8 | — |
| Jan 31, 2018 | $50.62 | $0.76 | 66.6 | — |
| Jan 31, 2017 | $46.25 | $0.45 | 102.8 | — |
n/m: not meaningful (a loss, or earnings close to zero). The daily P/E line is a chart indicator in the app.
Healthequity valuation against its peers
| Company | Market value | P/E | Forward P/E | Price / sales |
|---|---|---|---|---|
| HealthequityHQY | $8.57B | 37.0 | 20.0 | 6.3 |
| ImmunitybioIBRX | $8.68B | — | — | 52.4 |
| Arrowhead PharmaceuticalsARWR | $8.44B | — | — | 12.6 |
| Corcept TherapeuticsCORT | $8.71B | 193.1 | 25.7 | 10.5 |
| Spyre TherapeuticsSYRE | $8.38B | — | — | — |
| 10X GenomicsTXG | $8.90B | — | — | 14.4 |
| VaxcytePCVX | $8.96B | — | — | — |
| Praxis Precision MedicinesPRAX | $7.97B | — | — | — |
| Protagonist TherapeuticsPTGX | $9.32B | 140.6 | 61.9 | 33.0 |
| Peer median | 166.9 | 43.8 | 14.4 |
Reading these multiples
The P/E divides the share price by earnings per share over the last twelve months; the forward P/E divides it by the earnings analysts expect over the next twelve. Price to sales compares the company's market value with its revenue over the last twelve months. A multiple reads differently from one industry to the next, so the peer group above is the fairer comparison.
See also: HQY financials · HQY returns
No forecast, no recommendation. This page describes Healthequity Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.